In another mouse model of high-carbohydrate high-fat-diet-induced obesity, the cPLA2 inhibitor treatment attenuated visceral adiposity and improved most features of metabolic syndrome, including insulin sensitivity, glucose intolerance, and cardiovascular abnormalities [10]. Here, PLA2G4A is linked to obesity disorder.